Precision Medicine

Proscia and UCSF Partner to Deliver Artificial Intelligence Applications That Improve the Accuracy and Speed of Cancer Diagnosis

PHILADELPHIA & SAN FRANCISCO–(BUSINESS WIRE)–Proscia, a leading provider of artificial intelligence (AI) enabled digital pathology solutions, and the University of California, San Francisco (UCSF) have partnered to introduce artificial intelligence into the practice of pathology. Beginning with prostate cancer, the second leading cause of cancer deaths among men in the …

Read More »

Evelo Biosciences Announces Biomarker Data Showing EDP1815 is an Orally Delivered Dual Cytokine Inhibitor for Inflammatory Diseases

CAMBRIDGE, Mass., March 02, 2020 (GLOBE NEWSWIRE) — Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today announced biomarker data for EDP1815, its lead inflammation product candidate. Interim data from individuals in the ongoing Phase 1b clinical trial showed …

Read More »

GenapSys and Twist Partner to Bring Next-Generation Sequencing Target Enrichment and Library Preparation to Most Accessible Highly Accurate Sequencer

REDWOOD CITY, Calif. & SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–GenapSys Inc., the company behind the world’s first highly accurate, affordable, and portable gene sequencer, today announced a new OEM partnership with Twist Bioscience, a company enabling customers to succeed through its offering of high-quality synthetic DNA. The collaboration will bring a …

Read More »

NantOmics and NantHealth Announce Results of AI Software Study Demonstrating the Ability to Identify Aggressive Subtypes of Breast Cancer from Digital Pathology Images

CULVER CITY, Calif.–(BUSINESS WIRE)–NantOmics, LLC, the leader in molecular analysis, and NantHealth, Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company, announced today the publication of a peer-reviewed study in Breast Cancer Research, a Springer Nature journal, on a novel AI technique in breast cancer. The study reports on a novel deep-learning system of digital pathology …

Read More »

Biodesix Announces Initiation of Clinical Phase Biomarker Development Program with Merck KGaA and Pfizer

BOULDER, Colo.–(BUSINESS WIRE)–Biodesix, Inc. announced initiation of the next phase of their biomarker development program with Merck KGaA, Darmstadt, Germany and Pfizer Inc., New York, NY. The companies have completed initial discovery and development of a new proteomic test that identifies likely responders to the anti-PD-L1 checkpoint inhibitor (BAVENCIO®) (avelumab). …

Read More »

ProSciento and Nordic Bioscience Form Strategic Partnership to Develop Translational Biomarkers for Nonalcoholic Steatohepatitis

SAN DIEGO, Feb. 6, 2020 /PRNewswire/ –ProSciento, Inc., a clinical research organization (CRO) exclusively focused on NASH, diabetes, obesity and related metabolic diseases, announced today a strategic partnership with Nordic Bioscience, a precision drug development and biomarker technology company. The partnership will utilize ProSciento’s NASH PASS™ patient registry and Nordic …

Read More »

CD19 CAR NK-cell Therapy Achieves 73% Response Rate in Patients with Leukemia and Lymphoma

According to results from a Phase I/IIa trial at The University of Texas MD Anderson Cancer Center, treatment with cord blood-derived chimeric antigen receptor (CAR) natural killer (NK)-cell therapy targeting CD19 resulted in clinical responses in a majority of patients with relapsed or refractory non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL), …

Read More »

Personalis Launches a Comprehensive Genomic Cancer Profiling Test Enabling Advanced Composite Biomarkers for Cancer Treatment

MENLO PARK, Calif.–(BUSINESS WIRE)–Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the launch of the NeXT Dx™ Test to help oncologists identify potential therapies and clinical trial options for cancer patients. The Personalis NeXT Dx™ Test is one of the first cancer diagnostic platforms to …

Read More »

ArcherDX Announces Partnership with Illumina to Develop In-Vitro Diagnostic Tests

BOULDER, Colo., Dec. 3, 2019 /PRNewswire/ — ArcherDX, Inc., a growth-stage molecular diagnostics company dedicated to developing breakthrough solutions that advance personalized genomic medicine, today announced a non-exclusive partnership with Illumina, Inc. (NASDAQ: ILMN) to develop in-vitro diagnostic (IVD) tests for Archer’s planned portfolio of next-generation sequencing (NGS)-based companion diagnostics. …

Read More »

CarThera and KIYATEC Collaborate in Effort to Bring Personalized Medicine to Patients Stricken by Brain Cancer

GREENVILLE, S.C. & PARIS–(BUSINESS WIRE)–KIYATEC, Inc. and CarThera announce today that they have entered into a clinical collaboration for the purpose of advancing innovation and improving treatments for patients diagnosed with glioblastoma, a highly aggressive form of brain cancer that afflicts more than 130,000 patients worldwide per year and is characterized by historically …

Read More »